35
Participants
Start Date
October 9, 2014
Primary Completion Date
January 28, 2021
Study Completion Date
August 6, 2028
sorafenib
Given PO
everolimus
Given PO
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Sleepy Hollow, Sleepy Hollow
Memorial Sloan Kettering Westchester, Harrison
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Commack, Commack
Fox Chase Cancer Center, Philadelphia
Southeastern Medical Oncology Center-Goldsboro, Goldsboro
Wayne Memorial Hospital, Goldsboro
Southeastern Medical Oncology Center-Clinton, Clinton
Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Ohio State University Comprehensive Cancer Center, Columbus
University of Michigan Comprehensive Cancer Center, Ann Arbor
Siouxland Regional Cancer Center, Sioux City
Mercy Health System, Janesville
Mayo Clinic, Rochester
Northwestern University, Chicago
Nebraska Methodist Hospital, Omaha
Mayo Clinic in Florida, Jacksonville
Memorial Sloan Kettering Basking Ridge, Basking Ridge
Memorial Sloan Kettering Monmouth, Middletown
Memorial Sloan Kettering Bergen, Montvale
Collaborators (1)
National Cancer Institute (NCI)
NIH
Novartis
INDUSTRY
Alliance for Clinical Trials in Oncology
OTHER